Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Myeloid, Acute 20Lymphoma, Non-Hodgkin 19Hodgkin Disease 18Multiple Myeloma 17Myelodysplastic Syndromes 16Lymphoma 16Graft vs Host Disease 16Lymphoma, Mantle-Cell 15Leukemia, Lymphocytic, Chronic, B-Cell 15Leukemia 14Sarcoma 11Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 11Glioblastoma 11Tuberous Sclerosis 10Lymphoma, B-Cell, Marginal Zone 10Carcinoma, Renal Cell 10Neoplasms 9Hematologic Neoplasms 9Gliosarcoma 9Carcinoma, Hepatocellular 9Breast Neoplasms 9Brain Neoplasms 9Waldenstrom Macroglobulinemia 8Myeloproliferative Disorders 8Melanoma 8Burkitt Lymphoma 8Recurrence 7Neoplasm Metastasis 7

Interventions

Lovastatin 3Deoxycholic Acid 3AZD 6244 3pirfenidone 2Vinblastine 2Transcranial Direct Current Stimulation 2Sirolimus 2Polidocanol 2Lasers, Solid-State 2Inhalation 2Acetylcysteine 2tipifarnib 1pomalidomide 1peginterferon alfa-2b 1mirdametinib 1diphenylcyclopropenone 1binimetinib 1X-Rays 1Vincristine 1Temozolomide 1Surveys and Questionnaires 1Sunitinib 1Specimen Handling 1Sorafenib 1Saline Solution 1Ranibizumab 1Radiotherapy 1Photons 1Pharmacokinetics 1Neuropsychological Tests 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neurofibromatosis 1 × Sirolimus × Clear all
NCT03433183 2026-05-27

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Sarcoma Alliance for Research through Collaboration

Phase 2 Completed
21 enrolled 12 charts
CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

NCT00634270 2017-11-17

Protocol 102

University of Alabama at Birmingham

Phase 2 Completed
58 enrolled 19 charts
CNS

Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡